In healthcare settings, genetic tests to determine whether an individual had inherited a genetic mutation are ordered by a health professional, and the results are interpreted and conveyed to the patient by that person. However, direct to consumer genetic testing (DTCGT) has enabled individuals to purchase genetic tests and receive results without the intervention of a health professional. To inform a set of guidelines for consumers and health professionals, we undertook a systematic review of position statements, policies and recommendations on the use of DTCGT. We performed a search of seven databases and the Internet for relevant documents. The search terms were 'direct to consumer' and 'genetic test', and documents in English published from 2002 to 2011 were included. The search retrieved 314 items, of which 14 were eligible for review. Five themes were derived from thematic analysis: motivation for use, potential benefits, potential harms, recommendations to guide consumers and need for research. The authors of these documents described more potential harms than benefits, but, although some stated that direct to consumer testing should be actively discouraged, others supported consumer rights to make autonomous choices. Further research into the impact of direct to consumer testing on health services and consumers is required to inform policies.
Within health service frameworks, genetic tests for monogenic disorders are ordered by a health professional, and the results are interpreted and conveyed to the patient by that person. However, the advent of direct to consumer genetic testing (DTCGT) has enabled individuals to purchase a panel of genetic tests via the Internet and receive the results without the intervention of a health professional.
One of the factors raised in support of DTCGT is that it enhances the ability of the individual to make an autonomous choice to have a test that may influence his/her future health (1) . However, to make that choice the individual needs to be appropriately informed about the value, risks and benefits of the test. Lachance et al. ( 2) investigated 29 DTCGT websites and found that the information accompanying DTCGT was difficult to understand and in many cases essential information was omitted. Reinforcing the lack of clear, written information was the absence of opportunities provided for potential consumers to contact a health professional for guidance. In a study of normative documents on DTCGT, Senecal et al. (3) concluded that there were three approaches adopted by professional organizations towards DTCGT. At one end of the spectrum were those who called for a prohibition of such tests, while at the other end were the organizations that accepted DTCGT under certain controls or conditions (such as provision of appropriate information on a number of topics by the company). However, there were also groups in which the members appeared to be uncertain or in disagreement about the appropriate stance to take on this issue, termed the 'median group'. This indicates that even health professionals may be divided as to the appropriate position to adopt in relation to DTCGT. This issue was summarized by Evans and Green (4) (p568) as a 'culture war' between the DTC companies and the health professions, who suggested that there should be a greater transparency by companies about the clinical utility and validity of tests, ensuring that those of demonstrable value are clearly differentiated from those without an appropriate basis of scientific evidence. They further suggest that companies and health professionals should collaborate to direct and support consumers by agreeing on clear information regarding the use of DTCGTs for healthcare management.
Two aims of the EuroGentest2 project (http://www. eurogentest.org/) (a project to standardize and harmonize genetic testing in Europe) were to (i) develop guidance for the use of DTCGT for potential and actual consumers and (ii) provide information for health professionals as to the appropriate course of action if approached by consumers who were considering DTCGT or who requested support to deal with the results. To ensure we had knowledge of the current evidence before attempting this task, we undertook three systematic reviews, one on the views and experiences of consumers (5) and a second on attitudes and experiences of health professionals (6) . The third, reported here, focussed on current position statements and recommendations on the use of DTCGT.
Materials and methods

Study design
Conducting a systematic review is an effective way of identifying, analysing and synthesising a body of evidence in relation to a specific topic (7) . We used the procedure described by the Centre for Reviews and Dissemination (7), involving a focussed search for evidence using specific search terms and selection of relevant papers using rigorous inclusion and exclusion criteria. As this was a review of policies and recommendations, rather than research studies, we did not conduct a quality appraisal of the documents.
Search strategy
We searched relevant electronic databases and web pages. Details of the search are included in Table 1 . Documents published between 1 January 2001 and 1 February 2012 were eligible for inclusion.
The search terms used for this review were 'direct to consumer' and 'genetic test': we set the search to include any document in English in which the terms appeared anywhere in the heading or text. In a separate review (5), we tested the terms 'personalized medicine' or 'personal genom* in place of 'direct to consumer' and did not retrieve any additional documents using the alternative terms. The review included any document or paper (published in English) describing a position statement, policy, guideline or recommendations for use of DTC genetic testing related directly to health in any country and produced by a professional organization or other relevant body (e.g. bioethics committee). The following documents were excluded: those reporting research into the use or impact of DTC tests, those focussing primarily on DTC marketing of genetic tests, those focussing on DTC company strategies towards consumers, those focussing solely on nutrigenomic, ancestry or paternity tests, research investigating the views and attitudes of health professionals or consumers and discussion, opinion papers or commentaries.
Search results
The electronic database search retrieved 319 items, of which 14 were duplicates, leaving 305 for review. A total of 300 items were excluded based on reading the title and/or the abstract; the majority were reporting research into use of or attitudes towards DTCGT or were discussion or opinion papers. A further four items were found using a search of Google and Google Scholar. Finally, one item was retrieved through a search of relevant health professional websites and four by searching bioethics sites, resulting in 14 documents for the review.
Abstraction
Relevant details of each document were extracted ( Table 2 ). Each document was subjected to thematic analysis (8) . The text was coded for statements related to use of DTCGT (e.g. on perceived risks and benefits of DTCGT, recommendations or guidance), which were then grouped under themes. Because of word limits, only themes directly related to recommendations are reported here.
Results
Description of the documents
We identified eight documents produced by health professional organizations. Of these, six were professional colleges or societies based in the United States: the American College of Clinical Pharmacology (9), the American College of Medical Genetics (ACMG) (10), the American College of Obstetricians and Gynecologists (ACOG) (11) , the American Society of Clinical Oncology (ASCO) (12) , the American Society of Human Genetics (ASHG) (13, 14) and the National Society of Genetic Counselors (NSGC) (13) . One was produced by the European Society of Human Genetics (ESHG) (15) and another by the International Society of Nurses in Genetics (ISONG) (16) . Six additional documents were produced by public bodies: the Council of Europe (CoE) (17) , the independent UK body the Nuffield Council on Bioethics (NCB) (18) , the Belgian Advisory Committee on Bioethics (BAC) (19) , the Austrian Bioethics Commission (ABC) (20) , the National Council of Ethics for the Life Sciences (NCELS) (21) (Portugal) and by the UK government advisory body, the Human Genetics Commission (HGC) (22) . In all, 11 were produced by national bodies, 2 by regional bodies (CoE and ESHG) and 1 by an international organization (ISONG). Earlier versions of documents from these organizations were not included in the review as the later documents superseded them.
The document size range was 1 (NSGC) (13) to more than 20 pages (NCB) (18) . Documents produced by professional organizations were variously titled 'Statement', 'Position statement', 'Policy statement' or 'Opinion'. The definition of DTCGT used and recommendations for each document are summarized in Table 2 . Only the HGC (22) differentiated between tests that would indicate significant health or reproductive risk to the user and those related to nutrigenetics, lifestyle, phenotype, relatedness and ancestry tests.
Potential benefits
The right of individuals to have access to their own genetic information was emphasized by the ESHG (15), ABC (20) and BAC (19) as a function of personal autonomy; however, they also warned that such entitlement must be weighed against the performance of inappropriate tests (23) and threats to the well-being of the individual (19, 20) . The NCB18 stated that the benefits of such testing lay in the additional information available to the individual, while ISONG (16) took this further, suggesting that the information could have an empowering effect, and NSGC (13) stated that access to genetic testing could be enhanced through DTCGT.
The opportunity to avoid unneeded clinical investigations or screening, or to initiate early intervention, was cited by ASCO (12) and the NCB (18) as an advantage of using DTCGT. However, the concept of equitable access to tests for this purpose was stressed.
Potential harms
Among many potential harms cited, the most common concern was the risk that the consumer's privacy and confidentiality would not be respected, mentioned by all groups except the ACCP (9). The ESHG (15) suggested that consumers should determine what would happen to the sample and data if the company was sold subsequent to the testing. The potential for harm also included the chance that consumers may not realize that test results might have an influence on their future insurance or employment status (NCB, ASCO, ACOG, ASHG, ACMG) (7) (8) (9) 11, 18) . The actual cost to the consumer was only mentioned by the NCB (18) .
Another area of concern was the overstatement of the actual predictive power or utility of the results obtained through the tests (ABC, ACCP, ESHG, NCB, ISONG) (9, 15, 16, 18) , with some organizations (ACOG, ASCO, ESHG, ISONG, NCB) (11, 12, 15, 16, 18 ) also making the point that the results might be of questionable value to the purchaser as test validity and accuracy could be suspected. For this reason, the ESHG (15), ASCO (12), ACMG (10), ASHG (14) and CoE (17) all suggested that quality, clinical utility and clinical validity of the test should be the factors considered by the company when making a decision whether or not to offer the test and by the consumer when making a decision about buying a test. The chance that users might be inappropriately reassured by inaccurate test results or of misinterpreting results was seriously considered by the majority of organizations (ACOG, BAC, American College of Medical Genetics Focus not specified and no definition of DTCGT included given.
Minimum requirements:
ACMG statement on direct-to-consumer genetic testing
(1) knowledgeable health professionals should be involved in ordering and interpreting the test.
(2) the consumer should be fully informed, including regarding the scientific evidence for the test and issues around their own privacy (3) the laboratory must be accredited. DTCGT, direct to consumer genetic testing.
ESHG, ACMG, ASCO, NCB, ACCP, ISONG) (9-12, 15, 16, 18, 19) and the risk that consumers might make misinformed lifestyle or healthcare decisions due to this was flagged up by the BAC (19) , NCB (18) and ISONG (16) .
Recommendations to guide consumers
Four organizations appeared to directly oppose the availability of DTCGT without direct health professional intervention. NCELS (21) stated positively that such tests should not be available for diagnostic or predictive purposes, while ACOG (11) stated that use of such tests should be discouraged and both the ESHG (15) and ACMG (10) recommended that only genetic tests meeting stringent criteria should be available, and these should only be used with the support of health professionals. The members of the BAC (19) were divided, some believed all DTCGT should be banned, some considered that they could only be offered with support from medical staff and yet others felt they should be available with the provision of adequate information.
All documents in the review considered the potential for harm due to lack of understanding or information about the test, and particular recommendations focussed on information that should be available to consumers is summarized in Table 3 .
The HGC (22) principles list in detail the type of information that should be provided to the consumer to try to avoid this (Table 3) . Similarly, the NCB (18) recommended that information should be made available to consumers via publicly funded websites, thus enabling potential purchasers to obtain unbiased information related to the clinical validity, risks and benefits of DTCGT and the potential to receive results about conditions for which there may be no treatment. The possibility that results may also have an impact on the insurance or financial status of the person and that they may be obliged to disclose the results to third parties was also raised.
Strong recommendations were made about the need to involve trained and qualified health professionals to provide both accurate information and pre-and post-test counselling. Somewhat surprisingly, this was not mentioned by the statements produced by the ASHG (14) or ISONG (16) , although the ASHG claimed that professional organizations had a duty to educate professionals about DTCGT, while ISONG suggested that advice from a health professional should be available to consumers if they wished to access it. The ACCP (9) stressed that consumers should seek to discuss the information provided in any advertisement for DTCGT with a trusted health professional before having the test and to be aware that they would need support from a health professional to interpret the test results, while the CoE (17), NCELS (21) and HGC (22) identified specific types of test for which the involvement of a health professional was said to be mandatory. Concerns about possible conflicts of interest if the genetic counselor was also employed by the company selling the service were voiced by both the ACOG (11) and the ESHG (15) . The need to ensure that the tests were conducted by laboratories that were subject to regulated quality assurance procedures was cited by nine organizations (ACCP, ACMG, ASCO, BAC, ESHG, HGC, ISONG, NCELS and NSGC) (9, 10, 12, 13, 15, 16, 19, 21, 22) .
Additional issues
With respect to the possible untoward effect of use of DTCGT, the ABC, ACOG and ESHG warned that additional burdens may be placed on the healthcare systems as a result of consumers requiring information and support after proceeding with tests (11, 20, 23) . Further education of health professionals was considered necessary to support consumers undergoing DTCGT (ASHG, ASCO, BAC, ESHG, ISONG) (12, (14) (15) (16) 19) , especially to professionals to comprehend and explain the concept of low clinical utility.
In all documents where the topic was mentioned (13, 16, 18, 20, 22, 23) , it was suggested that it would be inappropriate to perform DTCGT on minors or persons unable to give informed consent.
The call for further research was tied to the issue that claims about the predictive power of tests might not be justified (ACOG, ACCP, ASHG, ISONG and NSGC) (9, 11, 13, 14, 16) . In addition, the NCB (18, 24) also called for further investigation into the effect of DTCGT on the health and psychological well-being of consumers.
Discussion
The results of this review suggest that professional and public bodies are more concerned about potential harms for patients that might ensue from DTCGT than they are supportive of possible benefits. In keeping with these concerns for consumer safety, Wright et al. (24) proposed a framework for DTCGT that would offer protection to consumers. The requirements suggested by those authors include appropriate consent procedures, performance of tests in accredited laboratories with trained staff to interpret results and adequate consumer protection legislation. However, the authors (24) also state that tests should only be offered where there is a proven association between the gene and the disease, but the nature of that proof is not specified. This would appear to be the crux of the matter, as strong evidence for gene-disease association is lacking for many tests already being offered (25, 26) . We would suggest that tests based on one single study lack proven analytical validity, but these are included in the DTCGT panel by some companies. For example, 23andme disclose in the 'Frequently asked questions' section of the website (https://www.23andme.com/you/faqwin/traitsingj/) that even what they class as 'Established Research' may be based on as few as two studies, while many of the tests they offer do not fit even this criterion.
German legislation introduced in 2009 made it illegal for a genetic test to be performed without the involvement of a medical doctor (27) . While regulation of genetic tests is considered in most of the statements in this review, Wright decried the legislation that effectively prohibits the use of DTCGT as paternalistic. In an editorial for the British Medical Journal, Hauskeller (28) claimed that national remedies through legislation may not be sufficient to protect consumers and that international standards must be applied, even though with regulation, there would still be a market for less rigorous forms of testing. In 2007, the Human Genetics Society of Australasia (HGSA) produced a 'scoping' document (29) to determine whether the HGSA should adopt a policy on DTCGT and concluded that, due to the access of individuals from any country to electronic media (including social networking), banning DTCGT advertisements may not be effective in reducing public awareness. The authors concluded that public education about the basis of DTCGT and the utility of results may be the only way to 'get rid of the market for DTC testing' (29) (p. 4) .
A recent review of consumer attitudes towards and experiences of DTCGT indicated that the majority of participants wanted guidance by a health professional when considering a test, as well as support to interpret the results (5). However, the review highlighted the paucity of research into the experiences of consumers. In only 2 of the 14 studies reviewed were data collected from individuals who had actually undergone DTCGT (30, 31) , limiting the generalizability of evidence. Almost all of the documents in the current study made reference to the need for consumers to have access to health professionals sufficiently knowledgeable about genetics to provide information on the relevance of the test for an individual and to support interpretation of results. However, Hennen et al. (32) studied 38 relevant company Internet sites and drew the conclusion that only a minority of companies suggest contact with a health professional before testing and, even where counselling is offered, this is usually by electronic means (e.g. email). Where there is inadequate health professional support for consumers, they may be unable to utilize the results and may turn to health professionals unconnected with the company for support. Concerns about the impact on health professional workload were expressed by both the ACOG (11) and the ESHG (15) , and this issue was also raised by Wade and Wilfond (33) , who believed that while genetic counselors were not obliged to order tests with uncertain clinical value for clients, they did have a responsibility to help clients to interpret results of tests they had purchased themselves. However, in countries where healthcare provision is based in primary care, general practitioners will be the first port of call for consumers.
Finally, guidelines for offering pre-symptomatic genetic testing include the need to offer pre-and posttest counselling (17) . As direct to consumer testing companies are now offering test that would come under the definition of pre-symptomatic testing (e.g. for mutations in the BRCA genes), those companies that do not offer counselling are clearly convening the standards of care for patients.
Conclusions
It is clear from this review that while professional bodies express concerns about the use of DTCGT, each has their own approach, and recommendations to ensure patient safety vary. As marketing of DTCGT is undertaken on an international level, a more coherent approach is needed to ensure that health professionals are well informed of both the potential advantages and risks to the patient. It may be difficult to produce one policy that is acceptable to all professional stakeholders; however, agreement on a 'code of practice' may be feasible. Specific recommendations could include:
(1) Agreement on the minimum information that should be available to the consumer to inform the decision to be tested and involvement of experienced health professionals in production of information. (2) Identification of tests that should not be offered without genuine access to genetic counselling from an appropriate health professional (included in the test fee). (3) Appropriate education for health professionals to enable them to offer advice and information to individuals.
It may be relevant for health professionals to lobby national policy makers and legislators to ensure that consumers (including minors and individuals in other vulnerable groups) are protected from harms that could arise from the injudicious use of DTCGT and to highlight the additional health resource required to enable individuals to make appropriate use of their test result. While it appears that policies have been produced by bioethics committees and professional organizations, much work is still needed to ensure that the benefits of making genetic tests more accessible are not outweighed by the harms.
